OncoMatch/Clinical Trials/NCT05304234
Liver Cancer Disparities in American Indian and Alaska Native Persons
Is NCT05304234 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Demographics
Lab requirements
Kidney function
GFR<30 excluded
Liver function
CTP score >=10 excluded; MELD-Na score >20 excluded
CTP score >=10; MELD-Na score >20; GFR<30
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cherokee Nation Health Service · Tahlequah, Oklahoma
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05304234 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages